BMS-275183: an orally active taxane in Phase I clinical trials (10/2001) [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 6918594 |
| CHEMBL ID | 4297268 |
| SCHEMBL ID | 13900214 |
| MeSH ID | M0402249 |
| Synonym |
|---|
| bms-275183 |
| uqc681jjiv , |
| unii-uqc681jjiv |
| 355113-98-3 |
| bms 275183 [who-dd] |
| SCHEMBL13900214 |
| DB12144 |
| Q27291199 |
| CHEMBL4297268 |
| [(1s,2s,3r,4s,7r,9s,10s,12r,15s)-12-acetyloxy-1,9-dihydroxy-15-[(2r,3s)-2-hydroxy-4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoyl]oxy-4-methoxycarbonyloxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (81.82) | 29.6817 |
| 2010's | 2 (18.18) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (33.33%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (66.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pantoprazole | aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide | anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | |
| paclitaxel | taxane diterpenoid; tetracyclic diterpenoid | antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent | 2001 | 2014 | 18.3 | high | 0 | 0 | 0 | 2 | 1 | 0 | |
| epothilone b | epothilone; epoxide | antineoplastic agent; apoptosis inducer; microtubule-stabilising agent | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
| epothilone a | epothilone; epoxide | antineoplastic agent; metabolite; microtubule-stabilising agent; tubulin modulator | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |
| ly335979 | carbopolycyclic compound | 2014 | 2014 | 10.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 | ||
| perfosfamide | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 | |||
| taxane | diterpene; terpenoid fundamental parent | 2003 | 2003 | 21.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ache | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Benign Neoplasms | 0 | 2004 | 2011 | 17.0 | medium | 3 | 0 | 0 | 3 | 1 | 0 | |
| Blood Poisoning | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Breast Cancer | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Breast Neoplasms | 0 | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Cancer of Colon | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Cancer of Lung | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Carcinoma, Non-Small Cell Lung | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Carcinoma, Non-Small-Cell Lung | 1 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Colonic Neoplasms | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Experimental Neoplasms | 0 | 2001 | 2004 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 | |
| Fatigue | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Lassitude | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Lung Neoplasms | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Neoplasms | 1 | 2004 | 2011 | 17.0 | medium | 3 | 0 | 0 | 3 | 1 | 0 | |
| Neutropenia | 0 | 2006 | 2011 | 15.5 | low | 2 | 0 | 0 | 1 | 1 | 0 | |
| Pain | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Sepsis | 0 | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Article | Year |
|---|---|
| A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-01, Volume: 13, Issue:13 | 2007 |
| Article | Year |
|---|---|
| Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-01, Volume: 14, Issue:13 | 2008 |
| Article | Year |
|---|---|
| "Effect of the drug transporters ABCB1, ABCC2, and ABCG2 on the disposition and brain accumulation of the taxane analog BMS-275,183". Investigational new drugs, , Volume: 32, Issue:6 | 2014 |
| BMS-275183-induced gene expression patterns in head and neck carcinoma. American journal of otolaryngology, , Volume: 28, Issue:5 | |
| The discovery of BMS-275183: an orally efficacious novel taxane. Bioorganic & medicinal chemistry, , Oct-01, Volume: 11, Issue:20 | 2003 |
| Article | Year |
|---|---|
| A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies. Investigational new drugs, , Volume: 29, Issue:6 | 2011 |
| Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-01, Volume: 14, Issue:13 | 2008 |
| A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183. Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-01, Volume: 13, Issue:13 | 2007 |
| Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer research, , Dec-01, Volume: 62, Issue:23 | 2002 |